Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group - Concepedia

Concepedia

Publication | Closed Access

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

3.8K

Citations

43

References

2007

Year

Malcolm J. Moore, David Goldstein, John Hamm, Arié Figer, J. Randolph Hecht, Steven Gallinger, H. Au, P. Murawa, David Walde, Robert A. Wolff,

Journal of Clinical Oncology

Abstract

To our knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine. The recommended dose of erlotinib with gemcitabine for this indication is 100 mg/d.

References

	Year	Citations

Page 1